MNPR Triangle 2.JPG
Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments
12 mai 2022 08h00 HE | Monopar Therapeutics Inc.
Validive® Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward InterimCamsirubicin Phase 1b Dose-Escalation Trial Clears 3rd Dose Level, Now Enrolling 4th WILMETTE, Ill., May 12, 2022 (GLOBE...
MNPR Triangle 2.JPG
Monopar Announces Clinical and Preclinical Program Updates
15 févr. 2022 08h05 HE | Monopar Therapeutics Inc.
Validive Phase 2b/3 VOICE trial now open at 43 sites; active and enrolling in US and EU Open-label Phase 1b camsirubicin trial: early signs of clinical benefit observed WILMETTE, Ill., Feb. 15,...
MNPR Triangle 2.JPG
Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO
24 juin 2021 08h00 HE | Monopar Therapeutics Inc.
WILMETTE, Ill., June 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
MNPR Triangle 2.JPG
Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer
03 juin 2021 08h00 HE | Monopar Therapeutics Inc.
WILMETTE, Ill., June 03, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
mono.jpg
Monopar and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic WILMETTE, Ill. and BELOIT, Wis., May 26, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional...
mono.jpg
Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery
24 mai 2021 08h00 HE | Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis., May 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional...
monopar.jpg
Monopar’s uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study
30 mars 2021 07h30 HE | Monopar Therapeutics Inc.
WILMETTE, Ill., March 30, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
monopar.jpg
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates
25 mars 2021 08h00 HE | Monopar Therapeutics Inc.
Validive® Phase 2b/3 VOICE Clinical Trial CommencedCamsirubicin Phase 2 Clinical Trial Anticipated to Start in Q2 2021MNPR-101-Conjugate Data Published in European Journal of Cancer WILMETTE,...
monopar.jpg
Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery
02 mars 2021 07h30 HE | Monopar Therapeutics Inc.
WILMETTE, Ill., March 02, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
monopar.jpg
Monopar Therapeutics to Present at Upcoming Investor Conferences
24 févr. 2021 07h30 HE | Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...